Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat

Am J Physiol Renal Physiol. 2018 Sep 1;315(3):F653-F664. doi: 10.1152/ajprenal.00143.2018. Epub 2018 May 23.

Abstract

The chronic intrinsic diuretic and natriuretic tone of sodium-glucose cotransporter 2 (SGLT2) inhibitors is incompletely understood because their effect on body fluid volume (BFV) has not been fully evaluated and because they often increase food and fluid intake at the same time. Here we first compared the effect of the SGLT2 inhibitor ipragliflozin (Ipra, 0.01% in diet for 8 wk) and vehicle (Veh) in Spontaneously Diabetic Torii rat, a nonobese type 2 diabetic model, and nondiabetic Sprague-Dawley rats. In nondiabetic rats, Ipra increased urinary excretion of Na+ (UNaV) and fluid (UV) associated with increased food and fluid intake. Diabetes increased these four parameters, but Ipra had no further effect, probably because of its antihyperglycemic effect, such that glucosuria and, as a consequence, food and fluid intake were unchanged. Fluid balance and BFV, determined by bioimpedance spectroscopy, were similar among the four groups. To study the impact of food and fluid intake, nondiabetic rats were treated for 7 days with Veh, Ipra, or Ipra+pair feeding+pair drinking (Pair-Ipra). Pair-Ipra maintained a small increase in UV and UNaV versus Veh despite similar food and fluid intake. Pair-Ipra induced a negative fluid balance and decreased BFV, whereas Ipra or Veh had no significant effect compared with basal values. In conclusion, SGLT2 inhibition induces a sustained diuretic and natriuretic tone. Homeostatic mechanisms are activated to stabilize BFV, including compensatory increases in fluid and food intake.

Keywords: SGLT2 inhibition; bioimpedance analysis; body fluid volume; diuresis; natriuresis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Body Composition / drug effects*
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / physiopathology
  • Diabetes Mellitus, Type 2 / urine
  • Disease Models, Animal
  • Diuresis / drug effects*
  • Drinking
  • Eating
  • Epithelial Sodium Channels / metabolism
  • Glucosides / toxicity*
  • Male
  • Natriuresis / drug effects*
  • Rats, Sprague-Dawley
  • Sodium / urine*
  • Sodium-Glucose Transporter 1 / metabolism
  • Sodium-Glucose Transporter 2 / metabolism*
  • Sodium-Glucose Transporter 2 Inhibitors / toxicity*
  • Sodium-Hydrogen Exchanger 3 / metabolism
  • Thiophenes / toxicity*
  • Time Factors
  • Water-Electrolyte Balance / drug effects

Substances

  • Epithelial Sodium Channels
  • Glucosides
  • Slc5a1 protein, rat
  • Slc5a2 protein, rat
  • Slc9a3 protein, rat
  • Sodium-Glucose Transporter 1
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors
  • Sodium-Hydrogen Exchanger 3
  • Thiophenes
  • ipragliflozin
  • Sodium